Dupilumab Shows Efficacy in Chronic Spontaneous Urticaria

Dupilumab查看药品详情 (Dupixent) has demonstrated significant efficacy in reducing itch and urticaria (搜索)搜索该疾病 in patients with chronic spontaneous urticaria (搜索)搜索该疾病 (CSU) whose symptoms are not adequately controlled with H1-antihistamine therapy. The phase III LIBERTY-CUPID study C revealed that dupilumab, when added to standard-of-care H1 antihistamines, led to a statistically significant reduction in itch severity compared to placebo.

Itch and Urticaria Severity Reduction

The study, presented at the American College of Allergy, Asthma & Immunology annual meeting, showed that patients receiving dupilumab查看药品详情 experienced an 8.64-point reduction in itch severity from baseline to week 24, compared to a 6.10-point reduction in the placebo group (P = 0.02). Itch severity was measured using the 21-point Itch Severity Score over 7 days (ISS7).

Furthermore, dupilumab查看药品详情 treatment resulted in a 15.86-point reduction in urticaria (搜索)搜索该疾病 activity (itch and hive) severity from baseline, while the placebo group saw an 11.21-point reduction (P = 0.02). Urticaria activity was assessed using the 42-point Urticaria Activity Score over 7 days (UAS7).

Clinical Significance

According to Dr. Thomas B. Casale, the data at week 24 indicated that nearly twice as many patients on dupilumab查看药品详情 achieved a UAS7 score of ≤6 (40.5% with dupilumab vs 23.5% with placebo), signifying well-controlled urticaria (搜索)搜索该疾病. Notably, approximately 30% of patients on dupilumab achieved complete remission (UAS7 score of 0) at 24 weeks, compared to 18% in the placebo group.

Study Design and Patient Population

The LIBERTY-CUPID study C, a placebo-controlled, double-blind, 24-week phase III trial, involved 151 patients aged 6 years or older. Participants were randomized to receive either dupilumab查看药品详情 (300 mg for adults and adolescents ≥60 kg, or 200 mg for adolescents <60 kg and children ≥30 kg) or a matching placebo subcutaneously every 2 weeks, in addition to their standard-of-care H1 antihistamines.

The patient demographics were consistent with typical urticaria (搜索)搜索该疾病 studies, with a predominantly female population (70%), a median age of approximately 45 years, and a median BMI of 27. The baseline ISS7 score was 15.1, and the baseline UAS7 score was 28.3. Roughly half of the patients were receiving a standard dose of antihistamines, while the other half were on a 2-to-4-fold standard dose.

Safety Profile

The safety profile of dupilumab查看药品详情 in this study was consistent with its known safety profile. Treatment-emergent adverse events (TEAEs) were similar in both groups (53%), with nasopharyngitis being the most common (8.1% with dupilumab and 5.2% with placebo). Injection site erythema was observed in 5.4% of patients in the dupilumab group. Severe TEAEs occurred in three patients in the dupilumab group and one in the placebo group, while serious TEAEs occurred in five patients in the dupilumab group and one on placebo.

Regulatory Implications

This study is designed to replicate LIBERTY-CUPID study A, which previously demonstrated dupilumab查看药品详情's efficacy in reducing itch and hive severity in omalizumab查看药品详情-naive patients. Study A supported the approval of dupilumab in Japan for CSU treatment in individuals aged 12 years and older whose condition is not adequately controlled with existing therapies. The results of Study C will support regulatory resubmission in the U.S. following an FDA Complete Response Letter requesting additional efficacy data. If approved, dupilumab would be the first targeted therapy for CSU in a decade, according to Sanofi查看公司主页.